Tiziana Life Sciences Ltd (TLSA)

Tiziana Life Sciences Ltd Borsa (TLSA) Ultime notizie

Tiziana seeks FDA Orphan Drug status for MS treatment By Investing.com - Investing.com Nigeria

Investing.com Nigeria

Tiziana eyes orphan drug designation for multiple sclerosis treatment - Proactive Investors USA

Proactive Investors USA

Tiziana Life Sciences' lead candidate demonstrates favorable safety profile and clinical response - Proactive Investors Australia

Proactive Investors Australia

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

GlobeNewswire Inc.

Tiziana Life Sciences unveils positive neuroimaging data for foralumab in MS patients - Proactive Investors USA

Proactive Investors USA

Tiziana Life Sciences wins FDA approval to add patients to MS program - Proactive Investors USA

Proactive Investors USA

Tiziana's MS Drug Shows Promising Patient Outcomes - TipRanks.com - TipRanks

TipRanks

Tiziana Life Sciences reports additional positive results from Multiple Sclerosis program - Proactive Investors UK

Proactive Investors UK

Tiziana Life Sciences' foralumab study highlighted in Neurology Today - Proactive Investors USA

Proactive Investors USA

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

GlobeNewswire Inc.

Tiziana Life Sciences says foralumab shows promise in stabilizing certain types of MS - Proactive Investors UK

Proactive Investors UK

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

GlobeNewswire Inc.

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

GlobeNewswire Inc.

Tiziana Showcases Foralumab's Neurotherapeutic Potential - TipRanks.com - TipRanks

TipRanks

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease

GlobeNewswire Inc.

Buy Tesla Stock for Humanoid Robots and Full-Self Driving?

Zacks Investment Research

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

GlobeNewswire Inc.

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

GlobeNewswire Inc.

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

GlobeNewswire Inc.

Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammation - Proactive Investors UK

Proactive Investors UK

Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar

GlobeNewswire Inc.

Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis

GlobeNewswire Inc.

Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple ... - Yahoo Finance

Yahoo Finance

Study evaluating intranasal anti-CD3 for treatment of Alzheimer's disease published in the PNAS journal - News-Medical.Net

News-Medical.Net

TLSA: Reduced Microglial Activation in PET Scan - Yahoo Finance

Yahoo Finance

Tiziana promotes chief medical officer Dr Matthew Davis to chief operating officer - Proactive Investors USA

Proactive Investors USA

Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab ... - BioSpace

BioSpace

Tiziana Life Sciences: Expansion into new clinical indications - Proactive Investors Australia

Proactive Investors Australia

Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For ... - Yahoo Finance

Yahoo Finance

EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients - Yahoo Finance

Yahoo Finance

Tiziana Life Sciences says intranasal foralumab presented at 'Preserving the Brain' scientific conference and exhibit in ... - Proactive Investors UK

Proactive Investors UK

Tiziana Life Sciences Ltd's (NASDAQ:TLSA) market cap rose US$30m last week; retail investors who hold 51% profited ... - Yahoo Finance

Yahoo Finance

Tiziana Life Sciences PLC: 2023 clinical outlook - Preview | NASDAQ:TLSA - Proactive Investors Australia

Proactive Investors Australia

Tiziana prioritizes 'lowest hanging fruit,' shelves unripe assets as threat of Nasdaq delisting looms - Fierce Biotech

Fierce Biotech

Tiziana looks to phase 1 trial for intranasal Alzheimer's drug - Labiotech.eu

Labiotech.eu

Tiziana Life Sciences presents intranasal foralumab at Preserving the Brain scientific conference in Italy - Proactive Investors UK

Proactive Investors UK

Tiziana Life Sciences reports continued improvements in second patient with secondary progressive multiple sclerosis ... - Proactive Investors UK

Proactive Investors UK

Is Tiziana Life Sciences Stock a buy? - Value the Markets

Value the Markets

Tiziana Life Sciences Ltd (NASDAQ:TLSA) Share Price | RNS News, Quotes, & Charts | TLSA | - Proactive Investors UK

Proactive Investors UK

Tiziana Life Sciences Ltd (NASDAQ: TLSA) Will Host the Key Opinion Leader Event - BP Journal

BP Journal

Tiziana Life Sciences set for Nasdaq move - Proactive Investors USA

Proactive Investors USA

Healthcare demands drive domestic UK biotech investment - Drug Target Review

Drug Target Review

Tiziana Life Sciences: The second-gen Covid-19 stocks offering explosive opportunities - Value the Markets

Value the Markets

Biotech Tiziana (TLSA) Stock Rally Might Be Confused With Tesla - Bloomberg

Bloomberg

Tiziana Life Sciences to spin out StemPrintER to 'maximise its value' - Proactive Investors UK

Proactive Investors UK

Tiziana Life Sciences (TLSA) Stock Price, News & Analysis - MarketBeat

MarketBeat

TLSA Stock Price and Chart — NASDAQ:TLSA - TradingView

TradingView

Healthy gains for Tiziana Life Sciences, MedaPhor Group, and Premaitha Health - Proactive Investors Australia

Proactive Investors Australia

Scientific founder of Intercept Pharmaceuticals joins Tiziana Life Sciences - European Pharmaceutical Review

European Pharmaceutical Review